Gly-Gly-Leu-OH
Need Assistance?
  • US & Canada:
    +
  • UK: +

Gly-Gly-Leu-OH

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Others
Catalog number
BAT-005014
CAS number
14857-82-0
Molecular Formula
C10H19N3O4
Molecular Weight
245.28
Gly-Gly-Leu-OH
IUPAC Name
(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-4-methylpentanoic acid
Synonyms
Glycyl-glycyl-L-leucine; (S)-2-(2-(2-Aminoacetamido)Acetamido)-4-Methylpentanoic Acid
Appearance
White crystalline powder
Purity
≥ 98% (HPLC)
Density
1.199 g/cm3
Boiling Point
573.7ºC at 760 mmHg
Storage
Store at -20°C
InChI
InChI=1S/C10H19N3O4/c1-6(2)3-7(10(16)17)13-9(15)5-12-8(14)4-11/h6-7H,3-5,11H2,1-2H3,(H,12,14)(H,13,15)(H,16,17)/t7-/m0/s1
InChI Key
XPJBQTCXPJNIFE-ZETCQYMHSA-N
Canonical SMILES
CC(C)CC(C(=O)O)NC(=O)CNC(=O)CN
1.Design of peptide standards with the same composition and minimal sequence variation to monitor performance/selectivity of reversed-phase matrices.
Mant CT1, Hodges RS. J Chromatogr A. 2012 Mar 23;1230:30-40. doi: 10.1016/j.chroma.2012.01.053. Epub 2012 Jan 25.
The present manuscript extends our de novo peptide design approach to the synthesis and evaluation of a new generation of reversed-phase HPLC peptide standards with the same composition and minimal sequence variation (SCMSV). Thus, we have designed and synthesized four series of peptide standards with the sequences Gly-X-Leu-Gly-Leu-Ala-Leu-Gly-Gly-Leu-Lys-Lys-amide, where the N-terminal is either N(α)-acetylated (Series 1) or contains a free α-amino group (Series 3); and Gly-Gly-Leu-Gly-Gly-Ala-Leu-Gly-X-Leu-Lys-Lys-amide, where the N-terminal is either N(α)-acetylated (Series 2) or contains a free α-amino group (Series 4). In this initial study, the single substitution position, X, was substituted with alkyl side-chains (Ala<Val<Ile, in order of increasing hydrophobicity) or aromatic side-chains (Phe, Tyr). Peptide series pairs 1/2 and 3/4 thus represent SCMSV peptides, with the substitution site, X, being towards the N- or C-terminal, albeit with identical adjacent residues (Gly-X-Leu) to maintain the same environment around position X.
2.Vascular effects of egg white-derived peptides in resistance arteries from rats. Structure-activity relationships.
Garcia-Redondo AB1, Roque FR, Miguel M, López-Fandiño R, Salaices M. J Sci Food Agric. 2010 Sep;90(12):1988-93. doi: 10.1002/jsfa.4037.
BACKGROUND: The vasodilator properties of several peptide sequences derived from egg white proteins were screened in mesenteric resistance arteries from Wistar-Kyoto rats. For this, third-order branches of the mesenteric arteries from 6-month-old male rats were used. The vasodilator responses, with or without endothelium, to several peptides (0.1 mmol L(-1)) were analysed in an isometric myograph. Moreover, the effect of nitric oxide (NO) synthase (L-NAME, 100 micromol L(-1)) and cyclooxygenase (indomethacin, 10 micromol L(-1)) inhibitors on the vasodilator response was tested.
3.Structural alteration in the pore motif of the bacterial 20S proteasome homolog HslV leads to uncontrolled protein degradation.
Park E1, Lee JW, Yoo HM, Ha BH, An JY, Jeon YJ, Seol JH, Eom SH, Chung CH. J Mol Biol. 2013 Aug 23;425(16):2940-54. doi: 10.1016/j.jmb.2013.05.011. Epub 2013 May 21.
In all cells, ATP-dependent proteases play central roles in the controlled degradation of short-lived regulatory or misfolded proteins. A hallmark of these enzymes is that proteolytic active sites are sequestered within a compartmentalized space, which is accessible to substrates only when they are fed into the cavity by protein-unfolding ATPases. HslVU is a prototype of such enzymes, consisting of the hexameric HslU ATPase and the dodecameric HslV protease. HslV forms a barrel-shaped proteolytic chamber with two constricted axial pores. Here, we report that structural alterations of HslV's pore motif dramatically affect the proteolytic activities of both HslV and HslVU complexes. Mutations of a conserved pore residue in HslV (Leu88 to Ala, Gly, or Ser) led to a tighter binding between HslV and HslU and a dramatic stimulation of both the proteolytic and ATPase activities. Furthermore, the HslV mutants alone showed a marked increase of basal hydrolytic activities toward small peptides and unstructured proteins.
4.A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1.
Zhang J1, Xue C1, Zhu T1, Vivekanandan A2, Pennathur S2, Ma ZA3, Chen YE1. PLoS One. 2013 Dec 27;8(12):e83509. doi: 10.1371/journal.pone.0083509. eCollection 2013.
The prevalence of type 2 diabetes (T2D) is rapidly increasing worldwide. Effective therapies, such as insulin and Glucagon-like peptide-1 (GLP-1), require injections, which are costly and result in less patient compliance. Here, we report the identification of a tripeptide with significant potential to treat T2D. The peptide, referred to as Diapin, is comprised of three natural L-amino acids, GlyGlyLeu. Glucose tolerance tests showed that oral administration of Diapin effectively lowered blood glucose after oral glucose loading in both normal C57BL/6J mice and T2D mouse models, including KKay, db/db, ob/ob mice, and high fat diet-induced obesity/T2D mice. In addition, Diapin treatment significantly reduced casual blood glucose in KKay diabetic mice in a time-dependent manner without causing hypoglycemia. Furthermore, we found that plasma GLP-1 and insulin levels in diabetic models were significantly increased with Diapin treatment compared to that in the controls.
Online Inquiry
Verification code
Inquiry Basket